Borealis Biosciences, Inc., a pioneering company at the forefront of RNA medicine, has successfully secured $420 million in funding to further its innovative mission of transforming the treatment landscape for kidney diseases and other debilitating conditions. Founded on a profound understanding that the confluence of scientific advancements and groundbreaking translational research holds the key to effective RNA therapies, Borealis aims to revolutionize how we address previously intractable medical challenges. The latest funding round was powered by the influential backing of Versant Ventures and pharmaceutical giant Novartis AG, which not only serves as a vital investor but also as a strategic collaborator. This infusion of capital will enable Borealis to accelerate its research and development efforts, advancing its proprietary RNA-based therapeutic pipeline. With a concerted focus on translating scientific discoveries into real-world medical solutions, Borealis is poised to drive significant advancements in treating kidney diseases, leveraging their expertise in RNA modalities. The support from leading investors underscores the industry鈥檚 confidence in Borealis鈥檚 unique approach and the potential impact of its innovations. As the company embarks on this exciting journey, it is dedicated to improving the lives of patients worldwide, harnessing the power of RNA to create effective therapies that address unmet medical needs. Borealis Biosciences stands on the threshold of groundbreaking advancements, and with this substantial funding, it reinforces its position as a trailblazer in the RNA medicine space.
Borealis Biosciences Secures $420M Funding for RNA Medicines Advancements in Kidney Disease Treatment
Recently funded 路 $420.0MBiotechnology Research
Get the full Borealis Biosciences, Inc. company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
